Dr Reddy's launches Sevelamer Carbonate in the US market
The newly launched Sevelamer Carbonate is in the strengths of 0.8 g and 2.4 g packets and is a therapeutic equivalent generic version of Renvela (sevelamer carbonate) for oral suspension, approved by the US Food and Drug Administration (USFDA), Dr Reddy's Laboratories said in a BSE filing.
New Delhi: Drug major Dr Reddy's Laboratories on Thursday announced the launch of Sevelamer Carbonate for oral suspension, used for controlling serum phosphorus in patients with chronic kidney disease on dialysis, in the US market.
The newly launched product is in the strengths of 0.8 g and 2.4 g packets and is a therapeutic equivalent generic version of Renvela (sevelamer carbonate) for oral suspension, approved by the US Food and Drug Administration (USFDA), Dr Reddy's Laboratories said in a BSE filing.
Quoting IMS Health data, the company said the Renvela brand and generic had US sales of approximately USD 101 million for the most recent 12 months ending in October 2018.
Next Story
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd